Project Grant R01CA316223
Award Date 9/2/26
Completion Date 8/31/31
Dollars Obligated $645K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
- The National Cancer Institute awarded Simplusdx, Inc. $532,105 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate a point-of-care screening test for hepatocellular carcinoma. Simplusdx will finalize development and clinically translate a point-of-care surveillance test for HCC using the D4 immunoassay platform, a nonfouling poly(oligoethylene glycol methyl ether methacrylate) brush that enables multiplexed, high-sensitivity...
- The National Cancer Institute awarded the University of Houston System $656,935 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop nanophotonic single exosome liquid biopsy technology for hepatocellular carcinoma screening and diagnosis. The project addresses limitations in current hepatocellular carcinoma surveillance methods, which rely on ultrasound and serum alfa-fetoprotein measurements that lack sensitivity and specificity for early...
- The National Cancer Institute awarded a cooperative agreement of $717,924 to The Trustees of Columbia University in the City of New York on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393). The award funds research examining environmental, genetic, and epigenetic risk factors for hepatocellular carcinoma (HCC) in U.S. populations, with particular focus on non-viral HCC cases. The research investigates associations between environmental toxins—including...
- The National Cancer Institute awarded Omicxhealth, Inc. $405,305 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394, Assistance Listing Project Grant R43CA310377) to develop OMICXSCREEN, an artificial intelligence and machine learning-powered blood test for early detection of hepatocellular carcinoma and esophageal cancer. OMICXSCREEN uses cell-free DNA methylation profiling via whole-genome bisulfite sequencing paired with a patent-pending...
- The National Cancer Institute awarded The Johns Hopkins University $249,000 on January 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop large-scale artificial intelligence using radiomics, deep learning, and physics-based generative modeling to improve clinical outcomes in nuclear medicine. The award funds three specific aims: construction of a large database of clinical positron emission tomography/computed tomography images with physician-annotated...
- The National Cancer Institute awarded the University of Illinois $412,249 on June 5, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop precision liver cancer models through CRISPR editing of primary human hepatocytes. The award funds development of a versatile platform to recapitulate hepatocellular carcinoma (HCC) molecular heterogeneity by introducing driver gene mutations commonly observed in human HCC into normal primary human hepatocytes, addressing critical...
- The National Cancer Institute awarded the University of Pittsburgh $261,662 on December 1, 2025, under the Cancer Research Manpower program (CFDA 93.398) to conduct an integrated in silico and in vivo genetic screening study identifying subtype-specific hepatocellular carcinoma genetic dependencies. The research combines computational deep-learning prediction of genetic dependencies with in vivo loss-of-function screening in murine hepatocellular carcinoma models representing the Hoshida...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Johns Hopkins University a $144,193 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) effective September 4, 2025 through August 31, 2030. This award provides protected salary support for Dr. Preethi Korangath to serve as a Laboratory Research Specialist in Dr. Robert Ivkov's laboratory, where she will facilitate the completion of Research Project Grants (R01) by leveraging her expertise...
- The National Cancer Institute awarded the University of North Carolina at Chapel Hill $399,829 on May 15, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and implement a population-based hepatocellular carcinoma surveillance registry and assess feasibility for identifying at-risk patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The award funds research to establish tools for a population-based HCC surveillance registry that...
- The National Institute of Biomedical Imaging and Bioengineering awarded The Johns Hopkins University $621,956 on August 12, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop artificial intelligence algorithms that detect very small pancreatic, hepatobiliary, and upper gastrointestinal cancers in computed tomography scans. The research addresses the late-stage detection problem in these disease categories, which...